Concepedia

Publication | Open Access

Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial

DOIFull Paper Access

41

Citations

38

References

2022

Year

Christina Brennan, Sandeep Nadella, Xiang Zhao, Richard Dima, Nicole Jordan–Martin, Breanna R. Demestichas, Sam O. Kleeman, Miriam Ferrer, Eva Gablenz, Nicholas Mourikis,
Gut

Abstract

Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomised trials are required.

References

YearCitations

Page 1